Becton, Dickinson and Company (BD) has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its blood collection and separation technology designed to enhance laboratory efficiency.

The BD Vacutainer Barricor plasma blood collection tube (BD Barricor), will enhance sample quality, helping clinicians to rapidly receive test results.

By replacing gel tubes, the BD Barricor single-use, plastic and evacuated tube will effectively obtain plasma from whole blood samples.

According to the company, the new mechanical separator technology reduces centrifugation time from 10 minutes to three minutes compared to gel tubes, as well as contamination by 50% to 65% compared to plasma gel tubes.

The company has designed the mechanical separator to absorb hydrophobic drugs. It can be used for therapeutic drug testing.

BD preanalytical systems worldwide president John Ledek said: “As we launch BD Barricor tubes in the U.S., we are effectively eliminating the tradeoff of superior sample quality versus quick turnaround often faced by laboratory technicians by providing both a cleaner and faster plasma sample than current methods.

“This revolutionary technological advancement can improve the accuracy and speed of clinical decision making, and result in enhanced patient care.”

Recently, the company also launched new Veritor Plus wireless rapid diagnostic system, which will etect influenza A and B, respiratory syncytial virus (RSV) and group A strep.

With new traceability and secure patient health record documentation features, the system can be used in physician offices, clinics, hospitals and integrated delivery networks (IDNs).

Image: BD’s Vacutainer Barricor plasma blood collection tube. Photo: courtesy of PRNewsFoto/BD (Becton, Dickinson and Compa).